RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 SORT-OUT VI: Zotarolimus-Eluting Stent Noninferior to Biolimus-Eluting Stent
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 19
SP 17
OP 18
DO 10.1177/155989771319003
UL http://mdc.sagepub.com/content/13/19/17.abstract
AB First-generation drug-eluting stents have reduced the risk of restenosis compared with bare-metal stents; however, these stents may have increased risk of stent thrombosis. Newer generation drug-eluting stents, which are constructed with biocompatible or biodegradable polymers, may have greater efficacy, safety, and device performance. The Randomized Clinical Comparison of Biomatrix Flex and Resolute Integrity trial [SORT-OUT VI; NCT01956448] compared the efficacy and safety of a zotarolimus-eluting stent with a biolimus-eluting stent in a population-based setting.